Hazlett, Burt & Watson’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$380K Sell
7,889
-1,932
-20% -$83K 0.1% 180
2026
Q1
$361K Sell
9,821
-888
-8% -$42.1K 0.11% 177
2025
Q4
$548K Sell
10,709
-1,583
-13% -$80.9K 0.18% 126
2025
Q3
$684K Buy
12,292
+463
+4% +$27.1K 0.24% 98
2025
Q2
$817K Buy
11,829
+1,516
+15% +$103K 0.33% 70
2025
Q1
$714K Sell
10,313
-148
-1% -$12.2K 0.32% 74
2024
Q4
$904K Buy
10,461
+741
+8% +$80.1K 0.4% 61
2024
Q3
$1.16M Buy
9,720
+12
+0.1% +$1.6K 0.53% 43
2024
Q2
$1.39M Buy
9,708
+408
+4% +$54.1K 0.72% 30
2024
Q1
$1.2M Buy
9,300
+266
+3% +$31.7K 0.72% 25
2023
Q4
$938K Buy
9,034
+3,494
+63% +$346K 0.63% 28
2023
Q3
$503K Buy
5,540
+86
+2% +$7.58K 0.37% 52
2023
Q2
$442K Buy
5,454
+16
+0.3% +$1.31K 0.33% 61
2023
Q1
$434K Hold
5,438
0.35% 57
2022
Q4
$368K Hold
5,438
0.32% 65
2022
Q3
$270K Hold
5,438
0.26% 81
2022
Q2
$304K Sell
5,438
-350
-6% -$19.4K 0.28% 75
2022
Q1
$320K Buy
+5,788
New +$297K 0.25% 84

Other funds holding NVO

Hazlett, Burt & Watson's NVO Position: Q2 2026 in Review

Hazlett, Burt & Watson reduced its Novo Nordisk (NVO) stake by 20% in Q2 2026, selling an estimated $83K and leaving 7,889 shares worth $380K. The position accounts for 0.1% of the portfolio, ranked #180.

Hazlett, Burt & Watson first reported a position in NVO in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.39M in Q2 2024. 1,354 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Hazlett, Burt & Watson held 7,889 shares of Novo Nordisk worth $380K as of Q2 2026.
  • Hazlett, Burt & Watson sold 1,932 Novo Nordisk shares in Q2 2026, an estimated $83K.
  • Novo Nordisk made up 0.1% of Hazlett, Burt & Watson's portfolio in Q2 2026, its #180 holding.
  • Hazlett, Burt & Watson first reported a position in Novo Nordisk in Q1 2022 and has held it in 18 quarters since.
  • Hazlett, Burt & Watson's Novo Nordisk position peaked at $1.39M in Q2 2024.
  • 1,354 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Hazlett, Burt & Watson's 13F filing for Q2 2026, filed 30 Jul 2026.